Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible...

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

Challenges of managing patients with NMIBC: from risk stratification to...

Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat

Challenges of managing patients with NMIBC: from risk stratification to treatment and beyond ( Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression...

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce...

Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce toxicity in older lymphoma patients ( Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland )

Optimising immunoglobulin dosing can enhance patient outcomes in multiple...

Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma ( Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA )

High-fibre dietary intervention in precursor plasma cell disorders improves...

Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma ( Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA )

Lack of benefit of auto-HCT in MCL patients in first complete remission with...

Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD ( Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA )

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Targeted therapies associated with increased risk for and incidence of...

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

More from ecancer